Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase I/II Study of Nivolumab in Combination with 5-azacytidine in pediatric patients with relapsed/refractory acute myeloid leukemia
Protocol ID
T2016-002
Disease (Sub Disease)
Leukaemia (AML)
Diagnosis Stage
Relapsed/ refractory
Location
NSW
Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Collaborators
Bristol-Myers Squibb
Trial Status
Open
Sites
Sydney Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
1 Year to 30 Years
International registry ID's
NCT03825367
Back to Registry
Study Title A Phase I/II Study of Nivolumab in Combination with 5-azacytidine in pediatric patients with relapsed/refractory acute myeloid leukemia
Protocol ID T2016-002
Disease (Sub Disease) Leukaemia (AML)
Diagnosis Stage Relapsed/ refractory
Location NSW
Sponsor Therapeutic Advances in Childhood Leukemia Consortium
Collaborators Bristol-Myers Squibb
Links https://clinicaltrials.gov/ct2/show/NCT03825367
Trial Status Open
Trial Open Date 22/11/2021
Sites Sydney Children's Hospital
Study Type Treatment
Phase Phase 1/2
Age Eligibility 1 Year to 30 Years
International registry ID's NCT03825367